NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Cogent Biosciences, Inc. COGT
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-2.16
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-73.7%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 9-year series below
Revenue
Net income
Per share
USD -2.16
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-73.7%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-52.0%
Each USD of equity lost 74 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−2.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.16B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 937.6M
total assets, end of FY2025
Total assetsUSD 937.6M
EquityUSD 636.4M
CashUSD 312.0M
Gross debtUSD 222.9M
Net debtUSD -89.1M
Current ratio14.23×
The company holds more cash than debt.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
·
·
·
·
·
0.0
0.0
0.0
0.0
Operating income $B
−0.3
−0.3
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.3
−0.3
−0.2
−0.1
·
·
·
·
·
Income tax $B
0.0
·
·
·
·
·
·
·
·
Net income $B
−0.3
−0.3
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−2.16
−1.94
−1.94
−1.73
−1.87
−16.17
−4.18
−1.39
−2.51
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−73.7
−99.5
−74.9
−59.7
−32.2
−56.2
−69.2
−606.5
·
Shares out B
0.16
0.11
0.09
0.07
0.04
0.03
0.01
0.03
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
25 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 2 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed